LaJolla Pharma launches mid-stage study of LJPC-401 in iron overload disorder
LaJolla Pharmaceuticals initiates a Phase 2 clinical trial assessing LJPC-401 (synthetic human hepcidin) in patients with hereditary hemochromatosis, a deficiency of ...
Continue Reading →
